{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T13:17:22Z","timestamp":1768828642561,"version":"3.49.0"},"reference-count":147,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100013041","name":"Shiraz University of Medical Sciences Vice Chancellor of Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004320","name":"Shiraz University of Medical Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004320","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.seizure.2021.05.010","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T12:04:28Z","timestamp":1621253068000},"page":"9-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Cosmetic adverse effects of antiseizure medications; A systematic review"],"prefix":"10.1016","volume":"91","author":[{"given":"Ali A.","family":"Asadi-Pooya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marzieh","family":"Rostaminejad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zahra","family":"Zeraatpisheh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nafiseh","family":"Mirzaei Damabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2021.05.010_bib0001","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1212\/WNL.0000000000003509","article-title":"Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies","volume":"88","author":"Fiest","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2021.05.010_bib0002","series-title":"Antiepileptic Drugs: a Clinician's Manual. Second Edition","author":"Asadi-Pooya","year":"2016"},{"key":"10.1016\/j.seizure.2021.05.010_bib0003","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/jocd.12192","article-title":"Women's attitudes to beauty, aging, and the place of cosmetic procedures: insights from the QUEST Observatory","volume":"15","author":"Ehlinger-Martin","year":"2016","journal-title":"J Cosmet Dermatol"},{"key":"10.1016\/j.seizure.2021.05.010_bib0004","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Int Med"},{"key":"10.1016\/j.seizure.2021.05.010_bib0005","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ijsu.2010.02.007","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"8","author":"Moher","year":"2010","journal-title":"Int J Surg"},{"key":"10.1016\/j.seizure.2021.05.010_bib0006","series-title":"on behalf of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","author":"Gronseth","year":"2017"},{"issue":"6","key":"10.1016\/j.seizure.2021.05.010_bib0007","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/0030-4220(72)90228-9","article-title":"Incidence of diphenylhydantoin gingival hyperplasia","volume":"34","author":"Angelopoulos","year":"1972","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"4","key":"10.1016\/j.seizure.2021.05.010_bib0008","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1469-8749.1973.tb05070.x","article-title":"Diphenylhydantoin-induced Gingival Hyperplasia: its relationship to dose and serum level","volume":"15","author":"Kapur","year":"1973","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0009","first-page":"369","article-title":"The gingival hyperplasia resulting from diphenylhydantoin in children and adults","volume":"12","author":"Matsumoto","year":"1975","journal-title":"Int J Clin Pharmacol Therapy Toxicol"},{"issue":"4","key":"10.1016\/j.seizure.2021.05.010_bib0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1111\/j.1469-8749.1975.tb03492.x","article-title":"Diphenylhydantoin-induced gingival hyperplasia: its response to changes in drug dosage","volume":"17","author":"Little","year":"1975","journal-title":"Dev Med Child Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2021.05.010_bib0011","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00007611-197701000-00009","article-title":"Effects of diphenylhydantoin in 41 epileptics institutionalized since childhood","volume":"70","author":"Herberg","year":"1977","journal-title":"South Med J"},{"issue":"8","key":"10.1016\/j.seizure.2021.05.010_bib0012","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1902\/jop.1980.51.8.474","article-title":"Dental root abnormalities and gingival overgrowth in epileptic patients receiving anticonvulsant therapy","volume":"51","author":"Girgis","year":"1980","journal-title":"J Periodontol"},{"issue":"6","key":"10.1016\/j.seizure.2021.05.010_bib0013","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/j.1600-051X.1982.tb02109.x","article-title":"Effects of anti-epileptic drug treatment with carbamazepine or phenytoin on the oral state of children and adolescents","volume":"9","author":"Lundstr\u00f6m","year":"1982","journal-title":"J Clin Periodontol"},{"issue":"6","key":"10.1016\/j.seizure.2021.05.010_bib0014","first-page":"417","article-title":"The measured effect of phenytoin withdrawal on gingival hyperplasia in children","volume":"52","author":"Brunsvold","year":"1985","journal-title":"ASDC J Dent Child"},{"issue":"6","key":"10.1016\/j.seizure.2021.05.010_bib0015","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1600-051X.1985.tb01377.x","article-title":"The effects of phenytoin and sodium valproate on the periodontal health of adult epileptic patients","volume":"12","author":"Seymour","year":"1985","journal-title":"J Clin Periodontol"},{"issue":"4","key":"10.1016\/j.seizure.2021.05.010_bib0016","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1528-1157.1986.tb03549.x","article-title":"Adverse reactions to antiepileptic drugs: a multicenter survey of clinical practice","volume":"27","author":"Beghi","year":"1986","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2021.05.010_bib0017","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1111\/j.1528-1157.1988.tb04237.x","article-title":"Clinical side effects of phenobarbital, primidone, phenytoin, carbamazepine, and valproate during monotherapy in children","volume":"29","author":"Herranz","year":"1988","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0018","first-page":"222","article-title":"Folate treatment of diphenylhydantoin-induced gingival hyperplasia","volume":"97","author":"B\u00e4ckman","year":"1989","journal-title":"Scand J Dent Res"},{"issue":"1","key":"10.1016\/j.seizure.2021.05.010_bib0019","first-page":"23","article-title":"Plasma level distribution, effect and toxicity of antiepileptic drugs among Ethiopian epileptics","volume":"28","author":"Bekele","year":"1990","journal-title":"Ethiop Med J"},{"issue":"9","key":"10.1016\/j.seizure.2021.05.010_bib0020","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1902\/jop.1990.61.9.571","article-title":"Diphenylhydantoin-induced gingival overgrowth in man: a clinico-pathological study","volume":"61","author":"Penarrocha-Diago","year":"1990","journal-title":"J Periodontol"},{"issue":"5","key":"10.1016\/j.seizure.2021.05.010_bib0021","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1097\/00007691-199510000-00002","article-title":"Phenytoin as a risk factor in gingival hyperplasia","volume":"17","author":"Perl\u00edk","year":"1995","journal-title":"Ther Drug Monit"},{"issue":"9003","key":"10.1016\/j.seizure.2021.05.010_bib0022","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0140-6736(96)90074-4","article-title":"Randomised comparative monotherapy trial of phenobarbitone, phenytoin, carbamazepine, or sodium valproate for newly diagnosed childhood epilepsy","volume":"347","author":"De Silva","year":"1996","journal-title":"Lancet (London, England)"},{"issue":"6","key":"10.1016\/j.seizure.2021.05.010_bib0023","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1902\/jop.1996.67.6.597","article-title":"Plasma and saliva concentrations of phenytoin and 5-(4-hydroxyphenyl)-5-phenylhydantoin in relation to the incidence and severity of phenytoin-induced gingival overgrowth in epileptic patients","volume":"67","author":"Ball","year":"1996","journal-title":"J Periodontol"},{"issue":"2","key":"10.1016\/j.seizure.2021.05.010_bib0024","first-page":"123","article-title":"Clinical psychometry and P3 in patients on phenytoin monotherapy","volume":"37","author":"Misra","year":"1997","journal-title":"Electromyogr Clin Neurophysiol"},{"issue":"3B","key":"10.1016\/j.seizure.2021.05.010_bib0025","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1590\/S0004-282X1999000500008","article-title":"Phenytoin as the first option in female epileptic patients?","volume":"57","author":"Trevisol-Bittencourt","year":"1999","journal-title":"Arq Neuropsiquiatr"},{"issue":"9","key":"10.1016\/j.seizure.2021.05.010_bib0026","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1046\/j.1365-2362.2001.00869.x","article-title":"Prevalence and risk of gingival enlargement in patients treated with anticonvulsant drugs","volume":"31","author":"Brunet","year":"2001","journal-title":"Eur J Clin Invest"},{"issue":"9265","key":"10.1016\/j.seizure.2021.05.010_bib0027","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1016\/S0140-6736(00)04516-5","article-title":"Epilepsy control with phenobarbital or phenytoin in rural south India: the Yelandur study","volume":"357","author":"Mani","year":"2001","journal-title":"Lancet (London, England)"},{"issue":"2","key":"10.1016\/j.seizure.2021.05.010_bib0028","first-page":"73","article-title":"Incidence of phenytoin induced gingival overgrowth in epileptic children: a six month evaluation","volume":"20","author":"Prasad","year":"2002","journal-title":"J Indian Soc Pedod Prev Dent"},{"issue":"4","key":"10.1016\/j.seizure.2021.05.010_bib0029","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.clineuro.2009.12.014","article-title":"Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients","volume":"112","author":"Zeng","year":"2010","journal-title":"Clin Neurol Neurosurg"},{"issue":"Suppl 3","key":"10.1016\/j.seizure.2021.05.010_bib0030","first-page":"S172","article-title":"Correlation between serum and salivary phenytoin concentrations in Thai epileptic children","volume":"94","author":"Liamsuwan","year":"2011","journal-title":"J Med Assoc Thai"},{"issue":"15","key":"10.1016\/j.seizure.2021.05.010_bib0031","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1212\/WNL.0b013e3182152844","article-title":"Folic acid supplementation prevents phenytoin-induced gingival overgrowth in children","volume":"76","author":"Arya","year":"2011","journal-title":"Neurology"},{"issue":"5919","key":"10.1016\/j.seizure.2021.05.010_bib0032","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1136\/bmj.2.5919.584","article-title":"Sodium valproate in treatment of epilepsy","volume":"2","author":"Jeavons","year":"1974","journal-title":"Br Med J"},{"issue":"6","key":"10.1016\/j.seizure.2021.05.010_bib0033","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1469-8749.1975.tb04698.x","article-title":"The Treatment of Childhood Epilepsy with Sodium Valproate","volume":"17","author":"Haigh","year":"1975","journal-title":"Dev Med Child Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0034","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1600-0404.1976.tb04797.x","article-title":"Sodium valproate in the treatment of resistant epilepsy","volume":"54","author":"Hassan","year":"1976","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10.1016\/j.seizure.2021.05.010_bib0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1600-0404.1979.tb02959.x","article-title":"Side effects of sodium valproate during long-term treatment in epilepsy","volume":"60","author":"Ruuskanen","year":"1979","journal-title":"Acta Neurol Scand"},{"issue":"10","key":"10.1016\/j.seizure.2021.05.010_bib0036","first-page":"461","article-title":"Valproic acid in childhood epilepsy: anticonvulsive efficacy in relation to its plasma levels","volume":"18","author":"Klotz","year":"1980","journal-title":"Int J Clin Pharmacol"},{"issue":"6291","key":"10.1016\/j.seizure.2021.05.010_bib0037","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1136\/bmj.283.6291.577","article-title":"Effects of sodium valproate in 100 children with special reference to weight","volume":"283","author":"Egger","year":"1981","journal-title":"Br Med J (Clinical research ed)"},{"issue":"2","key":"10.1016\/j.seizure.2021.05.010_bib0038","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1528-1157.1984.tb04171.x","article-title":"Intensive follow-up monitoring in patients with once daily evening administration of sodium valproate","volume":"25","author":"Stefan","year":"1984","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2021.05.010_bib0039","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1097\/00007691-198703000-00007","article-title":"Long-term treatment with sodium valproate: monitoring of venous ammonia concentrations and adverse effects","volume":"9","author":"Zaccara","year":"1987","journal-title":"Ther Drug Monit"},{"issue":"SUPPL","key":"10.1016\/j.seizure.2021.05.010_bib0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/0303-8467(92)90024-W","article-title":"First seizure in adults: to treat or not to treat","volume":"94","author":"Chandra","year":"1992","journal-title":"Clin Neurol Neurosurg"},{"issue":"11","key":"10.1016\/j.seizure.2021.05.010_bib0041","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJM199209103271104","article-title":"Department of Veterans Affairs Epilepsy Cooperative Study No G. A Comparison of Valproate with Carbamazepine for the Treatment of Complex Partial Seizures and Secondarily Generalized Tonic\u2013Clonic Seizures in Adults","volume":"327","author":"Mattson","year":"1992","journal-title":"New Engl J Med"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0042","doi-asserted-by":"crossref","first-page":"133","DOI":"10.5694\/j.1326-5377.1995.tb138476.x","article-title":"Juvenile myoclonic epilepsy: Diagnosis, management and outcome","volume":"162","author":"Sharpe","year":"1995","journal-title":"Med J Aust"},{"issue":"1","key":"10.1016\/j.seizure.2021.05.010_bib0043","first-page":"52","article-title":"Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy","volume":"21","author":"Murialdo","year":"1998","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"10.1016\/j.seizure.2021.05.010_bib0044","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1046\/j.1528-1157.2001.47000.x","article-title":"Low serum biotinidase activity in children with valproic acid monotherapy","volume":"42","author":"Schulpis","year":"2001","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.seizure.2021.05.010_bib0045","doi-asserted-by":"crossref","first-page":"527","DOI":"10.2165\/00044011-200323080-00005","article-title":"Association of polycystic ovaries with the use of valproic acid in Jordanian epileptic patients","volume":"23","author":"Otoom","year":"2003","journal-title":"Clin Drug Investig"},{"issue":"11","key":"10.1016\/j.seizure.2021.05.010_bib0046","first-page":"1651","article-title":"Chrono impact versus enteric coated valproate in Thai epileptic patients","volume":"88","author":"Towanabut","year":"2005","journal-title":"J Med Assoc Thailand"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0047","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.yebeh.2006.02.008","article-title":"Insulin-related metabolic changes during treatment with valproate in patients with epilepsy","volume":"8","author":"Pylv\u00e4nen","year":"2006","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2021.05.010_bib0048","first-page":"157","article-title":"Therapeutic drug monitoring of valproic acid in Mexican children","volume":"49","author":"Reyes-P\u00e9rez","year":"2006","journal-title":"Proc West Pharmacol Soc"},{"issue":"12","key":"10.1016\/j.seizure.2021.05.010_bib0049","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1111\/j.1528-1167.2006.00711.x","article-title":"The frequency of reversible parkinsonism and cognitive decline associated with valproate treatment: a study of 364 patients with different types of epilepsy","volume":"47","author":"Risti\u0107","year":"2006","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0050","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/j.1528-1167.2006.00953.x","article-title":"Endocrine effects of valproate in adolescent girls with epilepsy","volume":"48","author":"de Vries","year":"2007","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.seizure.2021.05.010_bib0051","first-page":"1402","article-title":"Short-term efficacy and safety of valproate sustained-release formulation in newly diagnosed partial epilepsy VIPe-study. A multicenter observational open-label study","volume":"28","author":"Deleu","year":"2007","journal-title":"Saudi Med J"},{"issue":"7","key":"10.1016\/j.seizure.2021.05.010_bib0052","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1528-1167.2007.01100.x","article-title":"Sodium valproate, hyperandrogenism and altered ovarian function in Indian women with epilepsy: a prospective study","volume":"48","author":"Prabhakar","year":"2007","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2021.05.010_bib0053","doi-asserted-by":"crossref","first-page":"313","DOI":"10.3923\/ijp.2009.313.318","article-title":"A randomized open-label comparison of lamotrigine and valproate in patients with juvenile myoclonic epilepsy","volume":"5","author":"Nejad","year":"2009","journal-title":"Int J Pharmacol"},{"issue":"5","key":"10.1016\/j.seizure.2021.05.010_bib0054","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejpn.2008.08.007","article-title":"The influence of valproic acid treatment on hair and serum zinc levels and serum biotinidase activity","volume":"13","author":"Yilmaz","year":"2009","journal-title":"Eur J Paediatr Neurol"},{"issue":"9","key":"10.1016\/j.seizure.2021.05.010_bib0055","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.seizure.2010.07.017","article-title":"Drug treatment failures and effectivity in children with newly diagnosed epilepsy","volume":"19","author":"Arhan","year":"2010","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.seizure.2021.05.010_bib0056","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1177\/0883073809336118","article-title":"Serum biotinidase activity in children treated with valproic acid and carbamazepine","volume":"25","author":"Castro-Gago","year":"2010","journal-title":"J Child Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0057","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1600-0404.2009.01308.x","article-title":"Valproate in children with newly diagnosed idiopathic generalized epilepsy","volume":"121","author":"Holland","year":"2010","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0058","first-page":"333","article-title":"Does steady state serum level of Valproic acid correlate with dose, seizure response and frequency of adverse drug reactions in Pakistani children with epilepsy?","volume":"9","author":"Noureen","year":"2011","journal-title":"J Pediatr Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0059","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eplepsyres.2012.06.004","article-title":"Sodium valproate for epilepsy in rural China: an efficacy and safety assessment in primary care","volume":"102","author":"Wang","year":"2012","journal-title":"Epilepsy Res"},{"issue":"8","key":"10.1016\/j.seizure.2021.05.010_bib0060","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.jocn.2012.10.020","article-title":"A randomized open-label observational study to compare the efficacy and tolerability between topiramate and valproate in juvenile myoclonic epilepsy","volume":"20","author":"Park","year":"2013","journal-title":"J Clin Neurosci"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0061","doi-asserted-by":"crossref","first-page":"6202","DOI":"10.4238\/2014.August.15.3","article-title":"Treatment gaps of epilepsy and retention rates of sodium valproate in rural Guangxi, China","volume":"13","author":"Huang","year":"2014","journal-title":"Genet Mol Res"},{"issue":"4","key":"10.1016\/j.seizure.2021.05.010_bib0062","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1055\/s-0033-1364104","article-title":"Reproductive endocrine health in pubertal females with epilepsy on antiepileptic drugs: Time to screen?","volume":"45","author":"Rauchenzauner","year":"2014","journal-title":"Neuropediatrics"},{"issue":"5","key":"10.1016\/j.seizure.2021.05.010_bib0063","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1111\/ane.12216","article-title":"Low-dose sodium valproate in the treatment of idiopathic generalized epilepsies","volume":"129","author":"Mir\u00f3","year":"2014","journal-title":"Acta Neurol Scand"},{"issue":"Pt A","key":"10.1016\/j.seizure.2021.05.010_bib0064","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.yebeh.2016.08.005","article-title":"Behavioral effects and somnolence due to levetiracetam versus oxcarbazepine - a retrospective comparison study of North Indian patients with refractory epilepsy","volume":"64","author":"Shukla","year":"2016","journal-title":"Epilepsy Behav\u202f: E&B"},{"key":"10.1016\/j.seizure.2021.05.010_bib0065","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.eplepsyres.2017.10.016","article-title":"Evaluate the effects of antiepileptic drugs on reproductive endocrine system in newly diagnosed female epileptic patients receiving either Valproate or Lamotrigine monotherapy: a prospective study","volume":"139","author":"Sidhu","year":"2018","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.seizure.2021.05.010_bib0066","first-page":"37","article-title":"Short-term side effects of low dose valproate monotherapy in epileptic children: a prospective study","volume":"13","author":"Nasr Esfahani","year":"2019","journal-title":"Iran J Child Neurol"},{"key":"10.1016\/j.seizure.2021.05.010_bib0067","first-page":"157","article-title":"Levetiracetam in genetic generalized epilepsy: a prospective unblinded active-controlled trial","author":"Tabrizi","year":"2019","journal-title":"Epilepsy Res"},{"issue":"6","key":"10.1016\/j.seizure.2021.05.010_bib0068","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1055\/s-2008-1071566","article-title":"Lamotrigine in resistant childhood epilepsy","volume":"24","author":"Battino","year":"1993","journal-title":"Neuropediatrics"},{"issue":"1","key":"10.1016\/j.seizure.2021.05.010_bib0069","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1053\/ejpn.2001.0402","article-title":"The long-term use of vigabatrin and lamotrigine in patients with severe childhood onset epilepsy","volume":"5","author":"Kluger","year":"2001","journal-title":"Eur J Paediatr Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2021.05.010_bib0070","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/0303-8467(94)90028-0","article-title":"Vigabatrin in uncontrolled seizures: Belgian clinical experience","volume":"96","author":"Lhoir","year":"1994","journal-title":"Clin Neurol Neurosurg"},{"issue":"1","key":"10.1016\/j.seizure.2021.05.010_bib0071","first-page":"51","article-title":"Hair loss - an adverse reaction to treatment with vigabatrin","volume":"22","author":"Lampl","year":"1996","journal-title":"Acta Ther"},{"issue":"4","key":"10.1016\/j.seizure.2021.05.010_bib0072","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.ejpn.2007.09.004","article-title":"Add-on levetiracetam in children and adolescents with refractory epilepsy: Results of an open-label multi-centre study","volume":"12","author":"Callenbach","year":"2008","journal-title":"Eur J Paediatr Neurol"},{"issue":"9","key":"10.1016\/j.seizure.2021.05.010_bib0073","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.seizure.2014.06.006","article-title":"Evaluation of levetiracetam and valproic acid as low-dose monotherapies for children with typical benign childhood epilepsy with centrotemporal spikes (BECTS)","volume":"23","author":"Xiao","year":"2014","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.seizure.2021.05.010_bib0074","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0387-7604(88)80098-6","article-title":"Bromides were effective in intractable epilepsy with generalized tonic-clonic seizures and onset in early childhood","volume":"10","author":"Ernst","year":"1988","journal-title":"Brain Dev"},{"issue":"4","key":"10.1016\/j.seizure.2021.05.010_bib0075","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1177\/0883073807302758","article-title":"Pharmacology, efficacy, and tolerability of potassium bromide in childhood epilepsy","volume":"22","author":"Korinthenberg","year":"2007","journal-title":"J Child Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2021.05.010_bib0076","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1159\/000008014","article-title":"An audit of the perceived efficacy and tolerability of gabapentin therapy in an out-patient cohort with chronic epilepsy","volume":"41","author":"Langan","year":"1999","journal-title":"Eur Neurol"},{"issue":"11","key":"10.1016\/j.seizure.2021.05.010_bib0077","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1046\/j.1528-1157.2001.30800.x","article-title":"Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study","volume":"42","author":"Deckers","year":"2001","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0078","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1528-1167.2007.00984.x","article-title":"Eslicarbazepine acetate: a double-blind, add-on, placebo-controlled exploratory trial in adult patients with partial-onset seizures","volume":"48","author":"Elger","year":"2007","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.seizure.2021.05.010_bib0079","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/j.seizure.2009.07.005","article-title":"Retention rate of pregabalin in drug-resistant epilepsy: 1-year follow-up, single-centre observation in 105 consecutive, adult patients","volume":"18","author":"Brandt","year":"2009","journal-title":"Seizure"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0080","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.yebeh.2008.12.013","article-title":"Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: First European experience","volume":"14","author":"Kluger","year":"2009","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0081","first-page":"271","article-title":"Study of the side effects of long-term anticonvulsant treatment","volume":"34","author":"Nakazawa","year":"1980","journal-title":"Folia Psychiatr Neurol Jpn"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0082","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2230.1992.tb00197.x","article-title":"Skin conditions in epileptics","volume":"17","author":"Swart","year":"1992","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0083","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/j.1468-3083.1993.tb00039.x","article-title":"Skin changes in epilepsy","volume":"2","author":"Yell","year":"1993","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0084","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0920-1211(97)00024-7","article-title":"A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy","volume":"27","author":"Bill","year":"1997","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0085","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S0920-1211(96)01013-3","article-title":"A double-blind controlled clinical trial: Oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy","volume":"26","author":"Christe","year":"1997","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0086","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1054\/jocn.1999.0190","article-title":"Significant anticonvulsant side-effects in children adolescents","volume":"7","author":"Harbord","year":"2000","journal-title":"J Clin Neurosci"},{"issue":"12","key":"10.1016\/j.seizure.2021.05.010_bib0087","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/j.1528-1167.2008.01676.x","article-title":"Seizure type, antiepileptic drugs, and reproductive endocrine dysfunction in Indian women with epilepsy: a cross-sectional study","volume":"49","author":"Sahota","year":"2008","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2021.05.010_bib0088","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5001\/omj.2010.5","article-title":"Correlation between serum level of antiepileptic drugs and their side effects","volume":"25","author":"Hussein","year":"2010","journal-title":"Oman Med J"},{"issue":"7","key":"10.1016\/j.seizure.2021.05.010_bib0089","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.seizure.2010.06.014","article-title":"Quality of life and treatment satisfaction in Spanish epilepsy patients on monotherapy with lamotrigine or valproic acid","volume":"19","author":"Viteri","year":"2010","journal-title":"Seizure"},{"issue":"5","key":"10.1016\/j.seizure.2021.05.010_bib0090","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1600-0404.2011.01488.x","article-title":"Self-reported symptoms in patients on antiepileptic drugs in monotherapy","volume":"124","author":"Wieshmann","year":"2011","journal-title":"Acta Neurol Scand"},{"issue":"4","key":"10.1016\/j.seizure.2021.05.010_bib0091","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WNF.0b013e31829a498d","article-title":"Adverse effects of antiepileptic drugs in north Indian pediatric outpatients","volume":"36","author":"Bansal","year":"2013","journal-title":"Clin Neuropharmacol"},{"issue":"2","key":"10.1016\/j.seizure.2021.05.010_bib0092","first-page":"144","article-title":"Comparision of efficacy and safety of Carbamazepine and Eslicarbazepine in adult partial and generalized seizures","volume":"7","author":"Jayasutha","year":"2014","journal-title":"Asian J Pharm Clin Res"},{"key":"10.1016\/j.seizure.2021.05.010_bib0093","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.yebeh.2014.10.021","article-title":"Cosmetic side effects of antiepileptic drugs in adults with epilepsy","volume":"42","author":"Chen","year":"2015","journal-title":"Epilepsy Behav\u202f: E&B"},{"issue":"5","key":"10.1016\/j.seizure.2021.05.010_bib0094","first-page":"464","article-title":"Standard approach to antiepileptic drug therapy in focal epilepsy at a tertiary care hospital in bengaluru: a retrospective cohort study","volume":"7","author":"Satish","year":"2017","journal-title":"Natl J Physiol Pharm Pharmacol"},{"key":"10.1016\/j.seizure.2021.05.010_bib0095","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8490639","article-title":"Adverse Events of antiepileptic drugs using indonesian version of Liverpool adverse events profile","volume":"2018","author":"Budikayanti","year":"2018","journal-title":"Neurol Res Int"},{"issue":"6","key":"10.1016\/j.seizure.2021.05.010_bib0096","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/epi.15664","article-title":"Pharmacological outcomes in teenagers with newly diagnosed epilepsy: a 30-year cohort study","volume":"60","author":"Alsfouk","year":"2019","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0097","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2174\/1574886314666190311112710","article-title":"Adverse drug reactions of anti-epileptic drugs in children with epilepsy: a cross-sectional study","volume":"14","author":"Kaushik","year":"2019","journal-title":"Curr Drug Saf"},{"issue":"4","key":"10.1016\/j.seizure.2021.05.010_bib0098","doi-asserted-by":"crossref","first-page":"e12479","DOI":"10.1111\/jicd.12479","article-title":"Oral health status of children with epilepsy in Hong Kong","volume":"10","author":"Yeung","year":"2019","journal-title":"J Investig Clin Dent"},{"key":"10.1016\/j.seizure.2021.05.010_bib0099","first-page":"105","article-title":"Evaluation of adverse drug reaction profile of antiepileptic drugs in persons with epilepsy: a cross-sectional study","author":"Kumar","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2021.05.010_bib0100","doi-asserted-by":"crossref","unstructured":"Gallo, C, Bonvento, G, Zagotto, G, Mucignat-Caretta, C. Gingival Overgrowth Induced by Anticonvulsant Drugs: a Cross-Sectional Study on Epileptic Patients. Periodontal research. 2021;(56);2; 363-369.","DOI":"10.1111\/jre.12828"},{"issue":"4","key":"10.1016\/j.seizure.2021.05.010_bib0101","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1111\/j.1600-0404.1977.tb01442.x","article-title":"One-sided gingival hyperplasia after treatment diphenylhydantoin","volume":"56","author":"Kristensen","year":"1977","journal-title":"Acta Neurol Scand"},{"issue":"5","key":"10.1016\/j.seizure.2021.05.010_bib0102","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/0030-4220(78)90144-5","article-title":"Diphenylhydantoinate-induced hyperplasia of the masticatory mucosa in an edentulous epileptic patient","volume":"45","author":"Dreyer","year":"1978","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"4","key":"10.1016\/j.seizure.2021.05.010_bib0103","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1111\/j.1365-2133.1980.tb07271.x","article-title":"Neonatal acne vulgaris: a possible feature of the fetal hydantoin syndrome","volume":"103","author":"Stankler","year":"1980","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.seizure.2021.05.010_bib0104","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1111\/j.1365-4362.1987.tb02317.x","article-title":"Phenytoin-lnduced Gum Hypertrophy Improved by Isotretinoin","volume":"26","author":"Norris","year":"1987","journal-title":"Int J Dermatol"},{"issue":"1","key":"10.1016\/j.seizure.2021.05.010_bib0105","first-page":"107","article-title":"Phenytoin hyperplasia occurring in relation to titanium implants: a clinical report","volume":"9","author":"Chee","year":"1994","journal-title":"Int J Oral Maxillofac Implants"},{"issue":"5","key":"10.1016\/j.seizure.2021.05.010_bib0106","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1056\/NEJM200002033420505","article-title":"Gingival hyperplasia induced by phenytoin","volume":"342","author":"Sharma","year":"2000","journal-title":"New Engl J Med"},{"issue":"10","key":"10.1016\/j.seizure.2021.05.010_bib0107","first-page":"741","article-title":"Acne, phenytoin and isotretinoin","volume":"19","author":"Marot","year":"2000","journal-title":"Nouv Dermatol"},{"issue":"1","key":"10.1016\/j.seizure.2021.05.010_bib0108","first-page":"41","article-title":"Are inflammatory cytokines potential mediators of phenytoin-induced gingival overgrowth?","volume":"31","author":"Buduneli","year":"2001","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.seizure.2021.05.010_bib0109","article-title":"Phenytoin-induced gingival enlargement: a dental awakening for patients with epilepsy","author":"Mohan","year":"2013","journal-title":"BMJ Case Rep"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0110","doi-asserted-by":"crossref","first-page":"272","DOI":"10.5530\/jyp.2015.3.20","article-title":"Phenytoin toxicity: a case report","volume":"7","author":"Menon","year":"2015","journal-title":"J Young Pharm"},{"issue":"5","key":"10.1016\/j.seizure.2021.05.010_bib0111","doi-asserted-by":"crossref","first-page":"561","DOI":"10.4103\/0972-124X.201693","article-title":"Management of phenytoin-induced gingival enlargement in a patient with antiphospholipid antibody syndrome: a rare case report","volume":"20","author":"Urolagin","year":"2016","journal-title":"J Indian Soc Periodontol"},{"issue":"2","key":"10.1016\/j.seizure.2021.05.010_bib0112","doi-asserted-by":"crossref","first-page":"157","DOI":"10.4103\/jdmimsu.jdmimsu_50_17","article-title":"A case of phenytoin induced multiple toxicities","volume":"12","author":"Khan","year":"2017","journal-title":"J Datta Meghe Inst Med Sci Univ"},{"issue":"2","key":"10.1016\/j.seizure.2021.05.010_bib0113","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1055\/s-0040-1709249","article-title":"Phenytoin-induced gingival overgrowth with predominant involvement of hard palate and floor of oral cavity: a case report and review of literature","volume":"11","author":"Sharma","year":"2020","journal-title":"J Neurosci Rural Pract"},{"issue":"1","key":"10.1016\/j.seizure.2021.05.010_bib0114","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S1059-1311(96)80062-8","article-title":"Methsuximide therapy of juvenile myoclonic epilepsy","volume":"5","author":"Hurst","year":"1996","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.seizure.2021.05.010_bib0115","first-page":"294","article-title":"Gingival overgrowth with valproic acid: s case report","volume":"64","author":"Anderson","year":"1997","journal-title":"J Dent Child"},{"issue":"3","key":"10.1016\/j.seizure.2021.05.010_bib0116","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1089\/met.2006.4.215","article-title":"Association of polycystic ovary syndrome with anticonvulsant use: s case report","volume":"4","author":"Sridhar","year":"2006","journal-title":"Metab Syndr Relat Disord"},{"issue":"5","key":"10.1016\/j.seizure.2021.05.010_bib0117","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1055\/s-2007-985901","article-title":"Congenital gingival hyperplasia in a neonate with foetal valproate syndrome","volume":"38","author":"Rodr\u00edguez-V\u00e1zquez","year":"2007","journal-title":"Neuropediatrics"},{"issue":"1","key":"10.1016\/j.seizure.2021.05.010_bib0118","first-page":"56","article-title":"Rare side effects of valproic acid: Gingival hyperplasia, and cervical lymphadenopathy","volume":"15","author":"Da\u01e7","year":"2013","journal-title":"Duzce Med J"},{"key":"10.1016\/j.seizure.2021.05.010_bib0119","article-title":"Global developmental delay with sodium valproate-induced gingival hyperplasia","author":"Patil","year":"2014","journal-title":"BMJ Case Rep"},{"issue":"9","key":"10.1016\/j.seizure.2021.05.010_bib0120","first-page":"FR01","article-title":"Sodium valproate induced alopecia: a case series","volume":"11","author":"Thomson","year":"2017","journal-title":"J Clin Diagn Res"},{"issue":"6","key":"10.1016\/j.seizure.2021.05.010_bib0121","first-page":"822","article-title":"Sodium valproate induced hyperammonemia with normal liver function: a case report","volume":"9","author":"Abraham","year":"2017","journal-title":"J Pharmaceut Sci Res"},{"issue":"6","key":"10.1016\/j.seizure.2021.05.010_bib0122","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0030-4220(81)90076-1","article-title":"Passive delayed eruption of the primary dentition secondary to Dilantin administration. Report of a case","volume":"52","author":"Reich","year":"1981","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"8","key":"10.1016\/j.seizure.2021.05.010_bib0123","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1111\/j.1365-4362.1990.tb03468.x","article-title":"Acne keloidalis-like lesions on the scalp associated with antiepileptic drugs","volume":"29","author":"Grunwald","year":"1990","journal-title":"Int J Dermatol"},{"issue":"11","key":"10.1016\/j.seizure.2021.05.010_bib0124","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1346-8138.1990.tb03011.x","article-title":"Anticonvulsant syndrome with multiple symptoms, including porphyria, IgA deficiency, and liver dysfunction","volume":"17","author":"Ono","year":"1990","journal-title":"J Dermatol"},{"issue":"4","key":"10.1016\/j.seizure.2021.05.010_bib0125","doi-asserted-by":"crossref","first-page":"190","DOI":"10.12968\/denu.2000.27.4.190","article-title":"Oral midazolam for adults with learning disabilities","volume":"27","author":"Boyle","year":"2000","journal-title":"Dent Update"},{"issue":"4","key":"10.1016\/j.seizure.2021.05.010_bib0126","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000069255","article-title":"Topiramate-induced hair loss: case report","volume":"3","author":"Chuang","year":"2002","journal-title":"Dermatol Psychosom"},{"issue":"2","key":"10.1016\/j.seizure.2021.05.010_bib0127","first-page":"199","article-title":"Severe phenytoin-induced gingival enlargement associated with periodontitis","volume":"56","author":"Lucchesi","year":"2008","journal-title":"Gen Dent"},{"issue":"2","key":"10.1016\/j.seizure.2021.05.010_bib0128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4103\/0253-7613.108315","article-title":"Serum drug level-related sodium valproate-induced hair loss","volume":"45","author":"Ramakrishnappa","year":"2013","journal-title":"Indian J Pharmacol"},{"issue":"12","key":"10.1016\/j.seizure.2021.05.010_bib0129","first-page":"924","article-title":"Carbamazepine-induced hair loss","volume":"19","author":"Shuper","year":"1985","journal-title":"Drug Intell Clin Pharm"},{"issue":"6","key":"10.1016\/j.seizure.2021.05.010_bib0130","first-page":"379","article-title":"A case of hair loss induced by carbamazepine","volume":"44","author":"Kohno","year":"2004","journal-title":"CLINNEUROL"},{"issue":"2","key":"10.1016\/j.seizure.2021.05.010_bib0131","first-page":"133","article-title":"Clinical and histopathological description of a new case of vigabatrin- induced gingival overgrowth","volume":"5","author":"Mesa Aguado","year":"2000","journal-title":"Med Oral"},{"issue":"10","key":"10.1016\/j.seizure.2021.05.010_bib0132","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.seizure.2014.06.016","article-title":"Epilepsy of infancy with migrating focal seizures: Six patients treated with bromide","volume":"23","author":"Caraballo","year":"2014","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.seizure.2021.05.010_bib0133","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.seizure.2013.11.007","article-title":"Hair loss with levetiracetam in five patients with epilepsy","volume":"23","author":"Zou","year":"2014","journal-title":"Seizure"},{"issue":"3 Pt 1","key":"10.1016\/j.seizure.2021.05.010_bib0134","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1600-051X.1996.tb02072.x","article-title":"The pathogenesis of drug-induced gingival overgrowth","volume":"23","author":"Seymour","year":"1996","journal-title":"J Clin Periodontol"},{"issue":"5","key":"10.1016\/j.seizure.2021.05.010_bib0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1111\/j.1600-0714.1991.tb00419.x","article-title":"On the mechanism of drug-induced gingival hyperplasia","volume":"20","author":"Brown","year":"1991","journal-title":"J Oral Pathol Med"},{"issue":"7","key":"10.1016\/j.seizure.2021.05.010_bib0136","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1034\/j.1600-051x.2000.027007506.x","article-title":"Factors influencing phenytoin-induced gingival enlargement","volume":"27","author":"Majola","year":"2000","journal-title":"J Clin Periodontol"},{"issue":"6","key":"10.1016\/j.seizure.2021.05.010_bib0137","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/j.1600-051X.1987.tb00983.x","article-title":"Effect of folate on phenytoin hyperplasia","volume":"14","author":"Drew","year":"1987","journal-title":"J Clin Periodontol"},{"issue":"4","key":"10.1016\/j.seizure.2021.05.010_bib0138","doi-asserted-by":"crossref","first-page":"319","DOI":"10.5005\/jp-journals-10024-1683","article-title":"Nonsurgical management of phenytoin-induced gingival hyperplasia","volume":"16","author":"AlJehani","year":"2015","journal-title":"J Contemp Dent Pract"},{"issue":"5","key":"10.1016\/j.seizure.2021.05.010_bib0139","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/0030-4220(91)90363-H","article-title":"The administration of folic acid to institutionalized epileptic adults with phenytoin-induced gingival hyperplasia. A double-blind, randomized, placebo-controlled, parallel study","volume":"71","author":"Brown","year":"1991","journal-title":"Oral Surg Oral Med Oral Pathol"},{"issue":"4","key":"10.1016\/j.seizure.2021.05.010_bib0140","doi-asserted-by":"crossref","first-page":"150","DOI":"10.4103\/ijt.ijt_10_18","article-title":"Valproate: it's effects on hair","volume":"10","author":"Kakunje","year":"2018","journal-title":"Int J Trichology"},{"issue":"12","key":"10.1016\/j.seizure.2021.05.010_bib0141","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1177\/0883073811409227","article-title":"The influence of valproic acid and carbamazepine treatment on serum biotin and zinc levels and on biotinidase activity","volume":"26","author":"Castro-Gago","year":"2011","journal-title":"J Child Neurol"},{"issue":"7","key":"10.1016\/j.seizure.2021.05.010_bib0142","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/epi.13021","article-title":"Valproate in the treatment of epilepsy in girls and women of childbearing potential","volume":"56","author":"Tomson","year":"2015","journal-title":"Epilepsia"},{"issue":"12","key":"10.1016\/j.seizure.2021.05.010_bib0143","first-page":"892","article-title":"Acne in adolescents","volume":"46","author":"Gebauer","year":"2017","journal-title":"Aust Fam Physician"},{"issue":"Suppl 2","key":"10.1016\/j.seizure.2021.05.010_bib0144","doi-asserted-by":"crossref","first-page":"S225","DOI":"10.1542\/peds.2019-2056L","article-title":"Current Issues in the Treatment of Acne Vulgaris","volume":"145","author":"Habeshian","year":"2020","journal-title":"Pediatrics"},{"key":"10.1016\/j.seizure.2021.05.010_bib0145","unstructured":"https:\/\/www.mayoclinic.org\/diseases-conditions\/acne\/diagnosis-treatment\/drc-20368048\/accessed on 2 April 2021."},{"issue":"6","key":"10.1016\/j.seizure.2021.05.010_bib0146","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/tan.13530","article-title":"HLA-associated antiepileptic drug-induced cutaneous adverse reactions","volume":"93","author":"Mullan","year":"2019","journal-title":"HLA"},{"issue":"1","key":"10.1016\/j.seizure.2021.05.010_bib0147","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1586\/17512433.2015.991716","article-title":"Antiepileptic drugs influences on body weight in people with epilepsy","volume":"8","author":"Hamed","year":"2015","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121001618?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121001618?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:58:21Z","timestamp":1761011901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131121001618"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":147,"alternative-id":["S1059131121001618"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2021.05.010","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cosmetic adverse effects of antiseizure medications; A systematic review","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2021.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}